CLL clonal evolution
cancer clonal evolution
ibrutinib resistance
combination of ibrutinib
CLL cells
pathogenesis of CLL
biology of CLL
BCR inhibition
oncogenic signals
BCR pathway
microenvironment-induced signals
mark CLL progression
therapeutic success of ibrutinib
ibrutinib-based combination treatments
critical role of BCR
working hypothesis
chronic lymphocytic leukemia Chronic lymphocytic leukemia
common leukemia
treatment resistance
mutation
selection
advantage of clinical trial
acquisition of by-pass mechanisms
co-clinical trial samples
treatment efficacy
contribution of cell
B-cell receptor
targeted agent
molecular lesions
important surface molecules
drugs
unprecedented opportunity
lack of suitable ex
models
patient outcome
adults
patients
interconnection
interactions
order
project
scenario